Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | GSR | P00390 | 2/20 | 0.64 |
| ▸ | GRM8 | O00222 | 2/20 | 0.64 |
| ▸ | GRM6 | O15303 | 2/20 | 0.64 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.64 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 1/20 | 0.64 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.64 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.64 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.64 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.64 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL2765120 | 1.00 | ALOX15 (0.83) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL9716079 | 1.00 | ALOX15 (0.83) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL9716082 | 1.00 | ALOX15 (0.83) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL869882 | 1.00 | ALOX15 (0.83) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL2765188 | 1.00 | ALOX15 (0.83) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL1675307 | 1.00 | ALOX15 (0.83) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL9754277 | 1.00 | ALOX15 (0.83) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL15543979 | 0.98 | ALOX15 (0.79) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL28756768 | 0.96 | ALOX15 (0.76) | ALOX15BLMPMP22KMT2AGSR | |
| Glutamine SCHEMBL27557033 | 0.93 | KMT2A (0.86) | ALOX15BLMPMP22KMT2AGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012612-B2 | Engineered immune cells with receptor signal strength modulated by a hinge | A2 BIOTHERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | claimed |
| CN-118119395-A | Synbiotic composition for metabolic management, in particular glucose metabolism management and regulation of satiety hormone levels | 赢创运营有限公司 | 2024-05-31 | — | — | CN | claimed |
| US-20220354812-A1 | COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR CANCER TREATMENT AND METABOLIC INTERVENTION THERAPY | FILTRICINE, INC. | 2022-11-10 | — | — | US | claimed |
| CN-115029304-A | Human oocyte activator and application thereof | 中国医科大学附属盛京医院 | 2022-09-09 | — | — | CN | claimed |
| US-11369127-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2022-06-28 | — | — | US | claimed |
| US-11147295-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC NATURAL PRODUCTS, LTD. (CN) | 2021-10-19 | — | — | US | claimed |
| CN-112041427-A | Synbiotic composition | 赢创运营有限公司 | 2020-12-04 | — | — | CN | claimed |
| US-20200352196-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2020-11-12 | — | — | US | claimed |
| US-20200337339-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2020-10-29 | — | — | US | claimed |
| EP-3544992-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | The Regents of The University of California (US) | 2019-10-02 | — | — | EP | claimed |
| EP-3107556-B1 | COMPOSITIONS FOR PREVENTING AND/OR TREATING PATHOLOGICAL CONDITIONS ASSOCIATED WITH ALPHA-GLUCOSIDASE | UNIV LA ROCHELLE (FR) | 2019-04-10 | — | — | EP | claimed |
| WO-2018098262-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | claimed |
| US-20150203546-A1 | SCYTODES VENOM FIBER PEPTIDES, NUCLEIC ACIDS AND METHODS OF MAKING AND USING | ZOBEL-THROPP PAMELA A (US) | 2015-07-23 | — | — | US | claimed |
| WO-2015016826-A1 | RUMINANT FEED COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BENEMILK OY (FI) | 2015-02-05 | — | — | WO | claimed |
| WO-2015016823-A1 | DIETARY PASTE COMPOSITIONS FOR RUMINANTS AND METHODS OF MAKING AND USING THE SAME | BENEMILK OY (FI) | 2015-02-05 | — | — | WO | claimed |
| WO-2015016827-A1 | DIETARY COMPOSITIONS FOR RUMINANTS AND CONTAINERS FOR STORING AND DISPENSING SAME | BENEMILK OY (FI) | 2015-02-05 | — | — | WO | claimed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-20030096976-A1 | Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies | HONG HYO JEONG (KR) | 2003-05-22 | — | — | US | claimed |
| US-4534881-A | Inhibition of inorganic or biological CaCO3 deposition by poly amino acid derivatives | UNIVERSITY OF SOUTH ALABAMA (US) | 1985-08-13 | — | — | US | claimed |
| EP-4734770-A1 | COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006362-A1 | COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024147108-A1 | FIBER PROTECTION AGENT, COMPOSITIONS AND USES THEREOF | SOLFARCOS - SOLUÇÕES FARMACEUTICAS E COSMETICAS LDA (PT) | 2024-07-11 | — | — | WO | disclosed |
| US-12031165-B2 | Double enzyme tandem preparation method of l-2-aminobutyric acid | JIANGNAN UNIVERSITY (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12029228-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC Natural Products Co., Ltd (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12012612-B2 | Engineered immune cells with receptor signal strength modulated by a hinge | A2 BIOTHERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-118119395-A | Synbiotic composition for metabolic management, in particular glucose metabolism management and regulation of satiety hormone levels | 赢创运营有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11985994-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC Natural Products Co., Ltd (CN) | 2024-05-21 | — | — | US | disclosed |
| US-11976297-B2 | Engineered immune cells with receptor cross-talk | A2 BIOTHERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240115481-A1 | FRAGRANCE RELEASE MECHANISM, METHOD AND USES THEREOF | UNIVERSIDADE DO MINHO (PT) | 2024-04-11 | — | — | US | disclosed |
| WO-2024059776-A2 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-117683078-A | Preparation method of glycyl-L-glutamine | 武汉桀升生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230384333-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-30 | — | — | US | disclosed |
| EP-4282473-A2 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | Akston Biosciences Corporation (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-117083071-A | Artificial alphavirus-derived RNA replicon expression system | 蒂巴生物技术有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117042628-A | Sweetener and flavor compositions containing terpene glycosides | 伊比西(北京)植物药物技术有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4271399-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-117015712-A | GPCR screening method for identifying non-magic compound | 加利福尼亚大学董事会 | 2023-11-07 | — | — | CN | disclosed |
| US-11793218-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| CN-112041427-B | Synbiotic composition | 赢创运营有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4073098-B1 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | AKSTON BIOSCIENCES CORP (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4244279-A1 | ELONGATED COMPOSITE FOR AN IMPLANT | 206 ORTHO, INC. (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116669751-A | TCR-T cell therapy targeting epstein-barr virus | 广东天科雅生物医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4229075-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | The Regents of the University of California (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230250148-A1 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION | 2023-08-10 | — | — | US | disclosed |
| US-20230248631-A1 | FRAGRANCE RELEASE MECHANISM, METHOD AND USES THEREOF | UNIVERSIDADE DO MINHO (PT) | 2023-08-10 | — | — | US | disclosed |
| EP-4223146-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023086839-A1 | SUNSCREEN COMPOSITIONS COMPRISING IMINE ANALOGS OF A SUNSCREEN COMPRISING A KETONE | CURIE CO. INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4175611-A1 | FRAGRANCE RELEASE MECHANISM, METHOD AND USES THEREOF | Universidade do Minho (PT) | 2023-05-10 | — | — | EP | disclosed |
| CN-115996693-A | Perfume delivery mechanism, method and use thereof | 米尼翁大学 | 2023-04-21 | — | — | CN | disclosed |
| EP-4152956-A1 | SWEETENER AND FLAVOR COMPOSITIONS CONTAINING TERPENE GLYCOSIDES | EPC Natural Products Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| CN-114958768-B | Preparation method of FGF10 paracrine general human fibroblast preparation | 健颐生物科技发展(山东)有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20230060800-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd (CN) | 2023-03-02 | — | — | US | disclosed |
| US-20230052393-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd (CN) | 2023-02-16 | — | — | US | disclosed |
| US-11555058-B2 | Cells engineered to express ultra-long acting insulin-Fc fusion proteins | AKSTON BIOSCIENCES CORPORATION (US) | 2023-01-17 | — | — | US | disclosed |
| US-20230000123-A1 | SWEETENER AND FLAVOR COMPOSITIONS CONTAINING TERPENE GLYCOSIDES | EPC Natural Products Co., Ltd (CN) | 2023-01-05 | — | — | US | disclosed |
| CN-112831451-B | Engineering bacterium for producing glutamine dipeptide and construction method and application thereof | 中国科学院微生物研究所 | 2022-09-16 | — | — | CN | disclosed |
| CN-115029304-A | Human oocyte activator and application thereof | 中国医科大学附属盛京医院 | 2022-09-09 | — | — | CN | disclosed |
| CN-114958768-A | Preparation method of FGF10 paracrine universal human fibroblast preparation | 健颐生物科技发展(山东)有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114846025-A | Ultra-long acting insulin-Fc fusion proteins and methods of use thereof | 阿卡斯通生物科学公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2022147056-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-4021465-A1 | ENGINEERED IMMUNE CELLS | A2 Biotherapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11369127-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| US-11352407-B2 | Ultra-long acting insulin-Fc fusion proteins | AKSTON BIOSCIENCES CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220160601-A1 | Sunscreen Compositions | CURIE CO. INC. | 2022-05-26 | — | — | US | disclosed |
| WO-2022104114-A1 | ELONGATED COMPOSITE FOR AN IMPLANT | 206 ORTHO, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3994159-A1 | METHODS FOR TREATING RAN PROTEIN-ASSOCIATED NEUROLOGICAL DISEASES | University of Florida Research Foundation, Incorporated (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022081631-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220104521-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd (CN) | 2022-04-07 | — | — | US | disclosed |
| CN-114262358-A | Preparation method of glutamine dipeptide | 苏州天马医药集团天吉生物制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220090015-A1 | ENGINEERED IMMUNE CELLS WITH MULTIPLEX AND LOCALIZED ACTIVITY | A2 BIOTHERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220090016-A1 | ENGINEERED IMMUNE CELLS WITH MICRO-CLUSTERS | A2 BIOTHERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2022061272-A1 | ENGINEERED IMMUNE CELLS | A2 BIOTHERAPEUTICS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220090013-A1 | ENGINEERING IMMUNE CELLS BASED ON ANTIGEN LEVELS | A2 BIOTHERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220089674-A1 | ENGINEERED IMMUNE CELLS THAT MODULATE RECEPTOR EXPRESSION | A2 BIOTHERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| CN-111172213-B | Method for preparing L-2-aminobutyric acid by double-enzyme tandem | 江南大学 | 2022-03-04 | — | — | CN | disclosed |
| CN-107406483-B | Microbial transglutaminase, substrates thereof, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-02-22 | — | — | CN | disclosed |
| WO-2022003655-A1 | FRAGRANCE RELEASE MECHANISM, METHOD AND USES THEREOF | UNIVERSIDADE DO MINHO (PT) | 2022-01-06 | — | — | WO | disclosed |
| US-20210403895-A1 | Double Enzyme Tandem Preparation Method of L-2-Aminobutyric Acid | JIANGNAN UNIVERSITY (CN) | 2021-12-30 | — | — | US | disclosed |
| WO-2021233242-A1 | SWEETENER AND FLAVOR COMPOSITIONS CONTAINING TERPENE GLYCOSIDES | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2021-11-25 | — | — | WO | disclosed |
| CN-107257802-B | Identification of transglutaminase substrates and uses thereof | 豪夫迈·罗氏有限公司 | 2021-11-23 | — | — | CN | disclosed |
| US-20210352940-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd (CN) | 2021-11-18 | — | — | US | disclosed |
| US-11147295-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC NATURAL PRODUCTS, LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| US-20210309709-A1 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2021143356-A1 | METHOD FOR PREPARING L-2-AMINOBUTYRIC ACID BY MEANS OF DOUBLE ENZYME SERIES CONNECTION | 江南大学 | 2021-07-22 | — | — | WO | disclosed |
| US-11054425-B2 | System and method for identification and characterization of transglutaminase species | Roche Sequencing Solutions, Inc. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2021126584-A1 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-112831451-A | Engineering bacterium for producing glutamine dipeptide and construction method and application thereof | 中国科学院微生物研究所 | 2021-05-25 | — | — | CN | disclosed |
| CN-107075475-B | Novel culture medium for removing undifferentiated stem cells and purifying refined myocardial cells | 心脏康复株式会社 | 2021-04-27 | — | — | CN | disclosed |
| US-20210101960-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-08 | — | — | US | disclosed |
| EP-3233884-B1 | MICROBIAL TRANSGLUTAMINASES, SUBSTRATES THEREFOR AND METHODS FOR THE USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-03-31 | — | — | EP | disclosed |
| EP-3790410-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd. (CN) | 2021-03-17 | — | — | EP | disclosed |
| EP-3790407-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd. (CN) | 2021-03-17 | — | — | EP | disclosed |
| US-20210051987-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20210045420-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| WO-2021007110-A1 | METHODS FOR TREATING RAN PROTEIN-ASSOCIATED NEUROLOGICAL DISEASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20200390113-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd (CN) | 2020-12-17 | — | — | US | disclosed |
| CN-112041427-A | Synbiotic composition | 赢创运营有限公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20200367543-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| US-20200371102-A1 | SYSTEM AND METHOD FOR IDENTIFICATION AND CHARACTERIZATION OF TRANSGLUTAMINASE SPECIES | Roche Sequencing Solutions, Inc. | 2020-11-26 | — | — | US | disclosed |
| US-20200359641-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd (CN) | 2020-11-19 | — | — | US | disclosed |
| US-20200352196-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| US-20200337339-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20200323243-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2020-10-15 | — | — | US | disclosed |
| US-10788495-B2 | System and method for identification and characterization of transglutaminase species | Roche Sequencing Solutions, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200249231-A1 | SYSTEM AND METHOD FOR IDENTIFICATION AND CHARACTERIZATION OF TRANSGLUTAMINASE SPECIES | Roche Sequencing Solutions, Inc. | 2020-08-06 | — | — | US | disclosed |
| US-10725049-B2 | Methods of detecting and measuring glutamine and analogues thereof, and methods related thereto | VICTORIA LINK LIMITED (NZ) | 2020-07-28 | — | — | US | disclosed |
| US-10675326-B2 | Compositions comprising cupredoxins for treating cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-09 | — | — | US | disclosed |
| CN-111172213-A | Method for preparing L-2-aminobutyric acid by double-enzyme tandem | 江南大学 | 2020-05-19 | — | — | CN | disclosed |
| EP-3170894-B1 | NEW UNDIFFERENTIATED STEM CELL REMOVAL AND MYOCARDIAL PURIFICATION AND REFINEMENT CULTURE MEDIUM | HEARTSEED INC (JP) | 2020-04-01 | — | — | EP | disclosed |
| US-10590177-B2 | Modifications of cupredoxin derived peptides | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019217310-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019217258-A1 | A TASTEFUL NATURAL SWEETENER AND FLAVOR | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019217312-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019217269-A1 | A TASTEFUL NATURAL SWEETENER AND FLAVOR | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019214567-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2019-11-14 | — | — | WO | disclosed |
| US-20190343155-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd (CN) | 2019-11-14 | — | — | US | disclosed |
| EP-3544992-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | The Regents of The University of California (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10407713-B2 | Reagent usable for the isolation and/or purification of nucleic acids | QIAGEN GMBH (DE) | 2019-09-10 | — | — | US | disclosed |
| US-10351605-B2 | Compositions and methods to prevent cancer by stabilizing p53 through non MDM2-mediated pathways | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-16 | — | — | US | disclosed |
| US-10336831-B2 | Use of anti-endoglin antibodies for treating ocular fibrosis | TRACON PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190046605-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-14 | — | — | US | disclosed |
| US-10196428-B2 | Modification of cupredoxin derived peptides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-05 | — | — | US | disclosed |
| US-20180327459-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER BY STABILIZING P53 THROUGH NON MDM2-MEDIATED PATHWAYS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-11-15 | — | — | US | disclosed |
| US-20180319848-A1 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-11-08 | — | — | US | disclosed |
| US-20180252714-A1 | System and Method for Identification and Characterization of Transglutaminase Species | ROCHE NIMBLEGEN INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180246116-A1 | METHODS OF DETECTING AND MEASURING GLUTAMINE AND ANALOGUES THEREOF, AND METHODS RELATED THERETO | VICTORIA UNIVERSITY OF WELLINGTON (NZ) | 2018-08-30 | — | — | US | disclosed |
| US-10005821-B2 | Modifications of cupredoxin derived peptides and methods of use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-06-26 | — | — | US | disclosed |
| US-10006915-B2 | System and method for identification and characterization of transglutaminase species | Roche Sequencing Solutions, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9995750-B2 | Methods of detecting and measuring glutamine and analogues thereof, and methods related thereto | VICTORIA LINK LIMITED (NZ) | 2018-06-12 | — | — | US | disclosed |
| CN-108138445-A | Method for making lignocellulosic paper and paper products | 索理思科技公司 | 2018-06-08 | — | — | CN | disclosed |
| WO-2018098262-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
| US-9968685-B2 | Methods to treat cancer with cupredoxins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-15 | — | — | US | disclosed |
| CN-107513074-A | A kind of benzoic acid derivative and its application | 成都大学 | 2017-12-26 | — | — | CN | disclosed |
| CN-107406483-A | Microbial transglutaminase, its substrate and its application method | 豪夫迈·罗氏有限公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-2729570-B1 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170327787-A1 | NEW UNDIFFERENTIATED STEM CELL REMOVAL AND MYOCARDIAL PURIFICATION AND REFINEMENT CULTURE MEDIUM | HEARTSEED INC. (JP) | 2017-11-16 | — | — | US | disclosed |
| EP-3233884-A1 | MICROBIAL TRANSGLUTAMINASES, SUBSTRATES THEREFOR AND METHODS FOR THE USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| CN-107257802-A | Discriminating of transglutaminase substrate and application thereof | 豪夫迈·罗氏有限公司 | 2017-10-17 | — | — | CN | disclosed |
| US-20170174729-A1 | MODIFICATION OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
| EP-3170894-A1 | NEW UNDIFFERENTIATED STEM CELL REMOVAL AND MYOCARDIAL PURIFICATION AND REFINEMENT CULTURE MEDIUM | Heartseed Inc. (JP) | 2017-05-24 | — | — | EP | disclosed |
| US-9611458-B2 | Method for preparing aqueous solution containing culture medium and chelating agent | KYOWA HAKKO KIRIN CO., LTD (JP) | 2017-04-04 | — | — | US | disclosed |
| US-9598470-B2 | Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2017-03-21 | — | — | US | disclosed |
| EP-1392293-B1 | METHOD FOR TREATMENT OF TUMORS USING NORDIHYDROGUAIARETIC ACID DERIVATIVES | UNIV JOHNS HOPKINS (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160299151-A1 | METHODS OF DETECTING AND MEASURING GLUTAMINE AND ANALOGUES THEREOF, AND METHODS RELATED THERETO | VICTORIA UNIVERSITY OF WELLINGTON (NZ) | 2016-10-13 | — | — | US | disclosed |
| US-9434770-B2 | Modified cupredoxin derived peptides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-06 | — | — | US | disclosed |
| US-20160183558-A1 | RUMINANT FEED COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BENEMILK OY (FI) | 2016-06-30 | — | — | US | disclosed |
| WO-2016100735-A1 | MICROBIAL TRANSGLUTAMINASES, SUBSTRATES THEREFOR AND METHODS FOR THE USE THEREOF | ROCHE NIMBLEGEN, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160178627-A1 | System and Method for Identification and Characterization of Transglutaminase Species | Roche Sequencing Solutions, Inc. | 2016-06-23 | — | — | US | disclosed |
| WO-2015084189-A1 | METHODS OF DETECTING AND MEASURING GLUTAMINE AND ANALOGUES THEREOF, AND METHODS RELATED THERETO | VICTORIA LINK LIMITED (NZ) | 2015-06-11 | — | — | WO | disclosed |
| EP-2844733-A1 | IN VITRO MODEL FOR PATHOLOGICAL OR PHYSIOLOGIC CONDITIONS | Hemoshear, LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2015016826-A1 | RUMINANT FEED COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BENEMILK OY (FI) | 2015-02-05 | — | — | WO | disclosed |
| US-20140287990-A1 | COMPOSITIONS AND METHODS TO CONCURRENTLY TREAT AND/OR PREVENT MULTIPLE DISEASES WITH CUPREDOXINS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-09-25 | — | — | US | disclosed |
| CN-103987284-A | CIGARETTE FILTER AND CIGARETTE | JAPAN TOBACCO INC | 2014-08-13 | — | — | CN | disclosed |
| US-20140154693-A1 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| EP-2729570-A2 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | Qiagen GmbH (DE) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013158939-A1 | IN VITRO MODEL FOR PATHOLOGICAL OR PHYSIOLOGIC CONDITIONS | HEMOSHEAR, LLC (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130267684-A1 | METHOD FOR PREPARING AQUEOUS SOLUTION CONTAINING CULTURE MEDIUM AND CHELATING AGENT | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| WO-2013004710-A2 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2013-01-10 | — | — | WO | disclosed |
| US-8349320-B2 | Compositions and methods for modulating responses mediated or associated with BTLA activity | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2521548-A2 | QUINAZOLIN-4(3A)-ONE DERIVATIVES AND METHODS OF USE THEREOF | Proteologics, Ltd (IL) | 2012-11-14 | — | — | EP | disclosed |
| US-8158574-B2 | Compositions and methods to prevent cancer with cupredoxins | CDG THERAPEUTICS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120077959-A1 | Asymmetric Cobalt-Catalyzed Cyclopropanation With Succinimidyl Diazoacetate | NATIONAL SCIENCE FOUNDATION | 2012-03-29 | — | — | US | disclosed |
| EP-2432870-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER BY STABILIZING P53 THROUGH NON MDM2-MEDIATED PATHWAYS | CDG Therapeutics, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| CN-102325542-A | Compositions and methods for preventing cancer with cupredoxins | CDG THERAPEUTICS INC | 2012-01-18 | — | — | CN | disclosed |
| CN-102316887-A | Compositions and method with the cupredoxin prophylaxis of cancer | CDG THERAPEUTICS INC | 2012-01-11 | — | — | CN | disclosed |
| EP-2379097-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS | CDG Therapeutics, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2379098-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS | CDG Therapeutics, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011064657-A2 | QUINAZOLIN-4(3A)-ONE DERIVATIVES AND METHODS OF USE THEREOF | PROTEOLOGICS, LTD. (IL) | 2011-06-03 | — | — | WO | disclosed |
| EP-2296693-A1 | COMPOSITIONS FOR ENHANCING THE ANTIBACTERIAL ACTIVITY OF MYELOPEROXIDASE AND METHODS OF USE THEREOF | Exoxemis, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010135299-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER BY STABILIZING P53 THROUGH NON MDM2-MEDIATED PATHWAYS | CDG THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100267608-A1 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-21 | — | — | US | disclosed |
| WO-2010094029-A2 | ASYMMETRIC CYCLOPROPANATION WITH SUCCINIMIDYL DIAZOACETATE | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-08-19 | — | — | WO | disclosed |
| CN-101809032-A | Method for selectively modifying proteins | NOVO NORDISK AS | 2010-08-18 | — | — | CN | disclosed |
| CN-101784282-A | vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates | GLAXOSMITHKLINE BIOLOG SA | 2010-07-21 | — | — | CN | disclosed |
| WO-2010080506-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS | CDG THERAPEUTICS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010078042-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS | CDG THERAPEUTICS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100104559-A1 | US CIP-COMPOSITIONS AND METHODS FOR MODULATING RESPONSES MEDIATED OR ASSOCIATED WITH BTLA ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-29 | — | — | US | disclosed |
| US-20100093057-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER BY STABILIZING P53 THROUGH NON MDM2-MEDIATED PATHWAYS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2010-04-15 | — | — | US | disclosed |
| US-20090311280-A1 | NOVEL TNF RECEPTOR REGULATORY DOMAIN | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2009-12-17 | — | — | US | disclosed |
| CN-101600447-A | The trim of cupredoxin derived peptides class and using method thereof | UNIV ILLINOIS (US) | 2009-12-09 | — | — | CN | disclosed |
| US-20090286719-A1 | MODIFICATION OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-11-19 | — | — | US | disclosed |
| WO-2009137697-A1 | COMPOSITIONS FOR ENHANCING THE ANTIBACTERIAL ACTIVITY OF MYELOPEROXIDASE AND METHODS OF USE THEREOF | EXOXEMIS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090215692-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS | CDG THERAPEUTICS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090208476-A1 | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-20 | — | — | US | disclosed |
| US-20090202441-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-20080131525-A1 | Therapeutic Nutrient Compositions Or Combinations And Methods Of Their Use | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2008-06-05 | — | — | US | disclosed |
| US-7351793-B2 | PRO1286 polypeptide | GENENTECH, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| CN-101084003-A | Therapeutic nutrient compositions or combinations and methods of their use | CRITICAL CARE CONNECTIONS INC (CA) | 2007-12-05 | — | — | CN | disclosed |
| EP-1841445-A1 | THERAPEUTIC NUTRIENT COMPOSITIONS OR COMBINATIONS AND METHODS OF THEIR USE | Critical Care Connections, Inc. (CA) | 2007-10-10 | — | — | EP | disclosed |
| EP-1833848-A2 | NOVEL TNF RECEPTOR REGULATORY DOMAIN | Lajolla Institute for Allergy and Immunology (US) | 2007-09-19 | — | — | EP | disclosed |
| US-7250296-B2 | Nucleotide sequences of 2S albumin gene and its promoter from grape and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1633377-B1 | A METHOD OF TREATING OR PREVENTING CHRONIC WOUNDS AND A COMPLETE NUTRITIONAL COMPOSITION COMPRISING GLYCINE AND/OR LEUCINE FOR USE THEREIN | NUTRICIA NV (NL) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006135447-A9 | VIRAL CHIMERA COMPOSITIONS AND METHODS | UNIV CALIFORNIA (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070042019-A1 | Method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein | N.V. NUTRICIA (NL) | 2007-02-22 | — | — | US | disclosed |
| WO-2006135447-A2 | VIRAL CHIMERA COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006063067-A9 | NOVEL TNF RECEPTOR REGULATORY DOMAIN | JOLLA INST ALLERGY IMMUNOLOG (US) | 2006-10-05 | — | — | WO | disclosed |
| CN-1833020-A | Pro104 antibody compositions and methods of use | DIADEXUS INC (US) | 2006-09-13 | — | — | CN | disclosed |
| CN-1821226-A | Antipicornaviral compounds, their preparation and use | AGOURON PHARMA (US) | 2006-08-23 | — | — | CN | disclosed |
| EP-1689863-A1 | TEMPLATE FIXED BETA-HAIRPIN LOOP MIMETICS AND THEIR USE IN PHAGE DISPLAY | Polyphor Ltd. (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006066404-A1 | THERAPEUTIC NUTRIENT COMPOSITIONS OR COMBINATIONS AND METHODS OF THEIR USE | CRITICAL CARE CONNECTIONS, INC. (CA) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006063067-A2 | NOVEL TNF RECEPTOR REGULATORY DOMAIN | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-1633377-A1 | A METHOD OF TREATING OR PREVENTING CHRONIC WOUNDS AND A COMPLETE NUTRITIONAL COMPOSITION COMPRISING GLYCINE AND/OR LEUCINE FOR USE THEREIN | N.V. Nutricia (NL) | 2006-03-15 | — | — | EP | disclosed |
| US-6913886-B2 | Fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides | INSTITUT PASTEUR (FR) | 2005-07-05 | — | — | US | disclosed |
| WO-2005047503-A1 | TEMPLATE FIXED ΒΕΤΑ-HAIRPIN LOOP MIMETICS AND THEIR USE IN PHAGE DISPLAY | POLYPHOR LTD. (CH) | 2005-05-26 | — | — | WO | disclosed |
| EP-0682709-B1 | METHOD FOR PRODUCING TOBACCO PROTEINASE NLA | UNIV TEXAS (US) | 2005-05-04 | — | — | EP | disclosed |
| CN-1198838-C | Anti-small RNA virus compound and preparation method and application thereof | AGOURON PHARMA (US) | 2005-04-27 | — | — | CN | disclosed |
| WO-2004103383-A1 | A METHOD OF TREATING OR PREVENTING CHRONIC WOUNDS AND A COMPLETE NUTRITIONAL COMPOSITION COMPRISING GLYCINE AND/OR LEUCINE FOR USE THEREIN | N.V. NUTRICIA (NL) | 2004-12-02 | — | — | WO | disclosed |
| US-20040208942-A1 | Alpha lipoic acid based food supplement for increasing lean muscle mass and strength | IOVATE T. & P. INC. (CA) | 2004-10-21 | — | — | US | disclosed |
| US-20040177404-A1 | Nucleotide sequences of 2S albumin gene and its promoter from grape and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2004-09-09 | — | — | US | disclosed |
| CN-1525957-A | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | ������ҩ������˾ | 2004-09-01 | — | — | CN | disclosed |
| US-20040023889-A1 | Alpha lipoic acid based food supplement for increasing lean muscle mass and strength | IOVATE T. & P. INC. (CA) | 2004-02-05 | — | — | US | disclosed |
| CN-1431995-A | Antipicornaviral compounds and compsns. their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMA (US) | 2003-07-23 | — | — | CN | disclosed |
| US-20030134268-A1 | Fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides | INSTITUT PASTEUR (FR) | 2003-07-17 | — | — | US | disclosed |
| US-6531284-B1 | Subjecting polynucleotide to a two-hybrid screening method (mating); selecting the recombinant diploid yeast cell for which the detectable gene has been expressed | INSTITUT PASTEUR (FR) | 2003-03-11 | — | — | US | disclosed |
| EP-1263780-A2 | LIV-1 RELATED PROTEIN, POLYNULCEOTIDES ENCODING THE SAME AND USE THEREOF FOR TREATMENT OF CANCER | GENENTECH, INC. (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1255454-A2 | ALPHA LIPOIC ACID BASED FOOD SUPPLEMENT TO INCREASE LEAN MUSCLE MASS AND STRENGTH | Muscletech Research and Development Inc. (CA) | 2002-11-13 | — | — | EP | disclosed |
| EP-1252145-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| CN-1372566-A | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMA (US) | 2002-10-02 | — | — | CN | disclosed |
| EP-0626850-B1 | DRY COMPOSITIONS FOR PREPARING SUBMICRON EMULSIONS | PHARMOS CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001055178-A9 | LIV-1 RELATED PROTEIN, POLYNUCLEOTIDES ENCODING THE SAME AND USE THEREOF FOR TREATMENT OF CANCER | GENENTECH INC (US) | 2002-04-04 | — | — | WO | disclosed |
| US-20020034570-A1 | Cheese flavoring | SYMRISE GMBH & CO. KG (DE) | 2002-03-21 | — | — | US | disclosed |
| US-20020006907-A1 | Alpha lipoic acid based food supplement for increasing lean muscle mass and strength | IOVATE T. & P. INC. (CA) | 2002-01-17 | — | — | US | disclosed |
| CN-1311793-A | Anti-small RNA virus compound and preparation method and application thereof | AGOURON PHARMA (US) | 2001-09-05 | — | — | CN | disclosed |
| WO-2001056402-A2 | ALPHA LIPOIC ACID BASED FOOD SUPPLEMENT TO INCREASE LEAN MUSCLE MASS AND STRENGTH | MUSCLETECH RESEARCH AND DEVELOPMENT INC. (CA) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001055178-A2 | LIV-1 RELATED PROTEIN, POLYNUCLEOTIDES ENCODING THE SAME AND USE THEREOF FOR TREATMENT OF CANCER | GENENTECH, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001040189-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6235500-B1 | BLOOD PROTEIN; FOR USE IN AMPLIFYING OXYGENATION OF ISOLATED ORGAN OR TISSUE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2001-05-22 | — | — | US | disclosed |
| US-6187535-B1 | ISOLATING PREFERENTIAL NUCLEOTIDE SEQUENCES CODING BINDING PROTEINS; PROVIDING YEAST CELL MIX, MATE AND PLATE YEAST, ISOLATE DIPLOID YEAST, CLASSIFY NUCLEOTIDE SEQUENCES IN DIPLOID YEAST CELL | INSTITUT PASTEUR (FR) | 2001-02-13 | — | — | US | disclosed |
| EP-0960130-A4 | OXYGEN-BINDING HEME PROTEINS INCORPORATING CIRCULARLY-PERMUTED GLOBINS | TRUSTEES FOR THE BOARD OF (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1055000-A1 | A FAST AND EXHAUSTIVE METHOD FOR SELECTING A PREY POLYPEPTIDE INTERACTING WITH A BAIT POLYPEPTIDE OF INTEREST: APPLICATION TO THE CONSTRUCTION OF MAPS OF INTERACTORS POLYPEPTIDES | INSTITUT PASTEUR (FR) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000053753-A2 | PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION | GENENTECH, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| EP-0960130-A1 | OXYGEN-BINDING HEME PROTEINS INCORPORATING CIRCULARLY-PERMUTED GLOBINS | The Board of Trustees for the University of Illinois (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999042612-A1 | A FAST AND EXHAUSTIVE METHOD FOR SELECTING A PREY POLYPEPTIDE INTERACTING WITH A BAIT POLYPEPTIDE OF INTEREST: APPLICATION TO THE CONSTRUCTION OF MAPS OF INTERACTORS POLYPEPTIDES | INSTITUT PASTEUR (FR) | 1999-08-26 | — | — | WO | disclosed |
| US-5888553-A | NUTRIENT FOR MUSCLE BUILDING; AMINOACID CHELATE COMPOUND | INFINITY, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| WO-1998044793-A1 | NON-STEROIDAL ANABOLIC COMPOSITION | ALBION LABORATORIES, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5807980-A | APROTININ DERIVATIVE | CORVAS INTERNATIONAL, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5770560-A | TREATING REDUCED HEMOGLOBIN OXYGEN AFFINITY IN MAMMALS | Fischer, James J. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5750142-A | LYOPHILIZED; CRYOPROTECTANTS; EMULSIFIERS; OIL IN WATER EMULSION | PHARMOS CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1998013386-A1 | OXYGEN-BINDING HEME PROTEINS INCORPORATING CIRCULARLY-PERMUTED GLOBINS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1998-04-02 | — | — | WO | disclosed |
| US-5693671-A | L-glutamine therapy for sickle cell diseases and thalassemia | HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE (US) | 1997-12-02 | — | — | US | disclosed |
| WO-1997026912-A9 | ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE | — | 1997-11-13 | — | — | WO | disclosed |
| US-5532142-A | PROTEINS FOR GENETIC ENGINEERING WITH DNA USING PROTEINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-07-02 | — | — | US | disclosed |
| US-5472706-A | Forming oil in water emulsion, adding cryoprotectant amino compound, diluting, lyophilizing; for pharmaceuticals, cosmetics | PHARMOS CORP. (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0682709-A1 | FUSION PROTEINS INCLUDING A CLEAVAGE SITE RECOGNIZED BY A PLANT VIRUS PROTEASE | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-11-22 | — | — | EP | disclosed |
| EP-0302801-B1 | Vaccines of which the characteristic epitope is incorporated in a picorna virus protein, particularly in that of the polio virus | PASTEUR INSTITUT (FR) | 1995-10-18 | — | — | EP | disclosed |
| EP-0626850-A4 | DRY COMPOSITIONS FOR PREPARING SUBMICRON EMULSIONS. | PHARMOS CORP (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5428007-A | Increasing oxygenation in hypoxic cells of normal and tumor tissue | YALE UNIVERSITY (US) | 1995-06-27 | — | — | US | disclosed |
| US-5393668-A | Culturing adherent cells | Doerr, Hans-Wilhelm (DE) | 1995-02-28 | — | — | US | disclosed |
| EP-0626850-A1 | DRY COMPOSITIONS FOR PREPARING SUBMICRON EMULSIONS | PHARMOS CORPORATION (US) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994018331-A2 | FUSION PROTEINS INCLUDING A CLEAVAGE SITE RECOGNIZED BY A PLANT VIRUS PROTEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1993015736-A1 | DRY COMPOSITIONS FOR PREPARING SUBMICRON EMULSIONS | PHARMOS CORP. (US) | 1993-08-19 | — | — | WO | disclosed |
| US-5182211-A | Plasmid vectors encoding a protein of a picornavirus | INSTITUT PASTEUR (FR) | 1993-01-26 | — | — | US | disclosed |
| US-5173426-A | Pure polynucleotide; for increasing tissue oxygenation in patients | YALE UNIVERSITY (US) | 1992-12-22 | — | — | US | disclosed |
| US-5162373-A | Gut Atrophy Prevention, Ornithine, Methionine | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-11-10 | — | — | US | disclosed |
| US-4952493-A | TETRAPEPTIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-08-28 | — | — | US | disclosed |
| WO-1989001516-A1 | VACCINES WHOSE CHARACTERISTIC EPITOPE IS INCORPORATED INTO A PROTEIN OF PICORNAVIRUS, IN PARTICULAR, POLIOVIRUS | INSTITUT PASTEUR (FR) | 1989-02-23 | — | — | WO | disclosed |
| EP-0302801-A1 | Vaccines of which the characteristic epitope is incorporated in a picorna virus protein, particularly in that of the polio virus | INSTITUT PASTEUR (FR) | 1989-02-08 | — | — | EP | disclosed |
| EP-0263903-A1 | Method for preparing specific inhibitors of virus-specified proteases | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-04-20 | — | — | EP | disclosed |
| US-4644055-A | HALOMETHYL KETONE OR METHYL KETONE COVALENTLY LINKED TO PEPTIDE SEQUENCE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-02-17 | — | — | US | disclosed |
| EP-0187721-A2 | Preparation of peptide substrates for virus-specified proteases | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
| EP-0187721-A2 | Preparation of peptide substrates for virus-specified proteases | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160601-A1 | Sunscreen Compositions | TYR, PLOD1, PLOD2 | ALOX15 976/4885BLM 2549/4885PMP22 4321/4885 |
| US-20090215692-A1 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS | BRCA1, PRDX6, PRDX1 | ALOX15 228/4885BLM 2030/4885PMP22 3411/4885 |
| US-20140287990-A1 | COMPOSITIONS AND METHODS TO CONCURRENTLY TREAT AND/OR PREVENT MULTIPLE DISEASES WITH CUPREDOXINS | PRDX5, CYC1, HMOX1 | ALOX15 141/4885BLM 3561/4885PMP22 1947/4885 |
| US-20230384333-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | HTR4, HTR6, HTR1A | ALOX15 3974/4885BLM 4150/4885PMP22 1232/4885 |
| US-20120077959-A1 | Asymmetric Cobalt-Catalyzed Cyclopropanation With Succinimidyl Diazoacetate | SI, STOM, SUCLA2 | ALOX15 4263/4885BLM 4510/4885PMP22 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.